Canada - engelsk - Health Canada

mylan pharmaceuticals ulc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 2mg; 0.5mg - buprenorphine (buprenorphine hydrochloride) 2mg; naloxone (naloxone hydrochloride dihydrate) 0.5mg - opiate partial agonists

Canada - engelsk - Health Canada

mylan pharmaceuticals ulc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 8mg; 2mg - buprenorphine (buprenorphine hydrochloride) 8mg; naloxone (naloxone hydrochloride dihydrate) 2mg - opiate partial agonists

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: povidone; oleyl oleate; polyethylene; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 15 mg - drug delivery system, transdermal - excipient ingredients: povidone; polyethylene; levulinic acid; oleyl oleate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: povidone; polyethylene; levulinic acid; oleyl oleate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Canada - fransk - Health Canada

teva canada limited - buprénorphine (chlorhydrate de buprénorphine); naloxone (chlorhydrate dihydraté de naloxone) - comprimé - 8mg; 2mg - buprénorphine (chlorhydrate de buprénorphine) 8mg; naloxone (chlorhydrate dihydraté de naloxone) 2mg - opiate partial agonists

Canada - fransk - Health Canada

mylan pharmaceuticals ulc - buprénorphine (chlorhydrate de buprénorphine); naloxone (chlorhydrate dihydraté de naloxone) - comprimé - 2mg; 0.5mg - buprénorphine (chlorhydrate de buprénorphine) 2mg; naloxone (chlorhydrate dihydraté de naloxone) 0.5mg - opiate partial agonists

Canada - fransk - Health Canada

mylan pharmaceuticals ulc - buprénorphine (chlorhydrate de buprénorphine); naloxone (chlorhydrate dihydraté de naloxone) - comprimé - 8mg; 2mg - buprénorphine (chlorhydrate de buprénorphine) 8mg; naloxone (chlorhydrate dihydraté de naloxone) 2mg - opiate partial agonists

Canada - fransk - Health Canada

pharmascience inc - buprénorphine (chlorhydrate de buprénorphine); naloxone (chlorhydrate dihydraté de naloxone) - comprimé - 2mg; 0.5mg - buprénorphine (chlorhydrate de buprénorphine) 2mg; naloxone (chlorhydrate dihydraté de naloxone) 0.5mg - opiate partial agonists